197 related articles for article (PubMed ID: 33558380)
1. Acute renal transplant rejection following nivolumab therapy for metastatic melanoma.
Tan B; Baxter M; Casasola R
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33558380
[TBL] [Abstract][Full Text] [Related]
2. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.
Hurkmans DP; Verhoeven JGHP; de Leur K; Boer K; Joosse A; Baan CC; von der Thüsen JH; van Schaik RHN; Mathijssen RHJ; van der Veldt AAM; Hesselink DA
J Immunother Cancer; 2019 Jul; 7(1):182. PubMed ID: 31300068
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
5. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
6. Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report.
Soellradl I; Kehrer H; Cejka D
Transplant Proc; 2020 Mar; 52(2):657-659. PubMed ID: 32044081
[TBL] [Abstract][Full Text] [Related]
7. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
[No Abstract] [Full Text] [Related]
8. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.
Zehou O; Leibler C; Arnault JP; Sayegh J; Montaudié H; Rémy P; Glotz D; Cordonnier C; Martin L; Lebbé C
Am J Transplant; 2018 Dec; 18(12):3065-3071. PubMed ID: 30107088
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
12. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
13. The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
Hanna DL; Law SJ; Merrick SA; Heptinstall L; Bass P; Dupont P; Sheri A
Melanoma Res; 2020 Jun; 30(3):321-324. PubMed ID: 31764435
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors.
Mitropoulou G; Daccord C; Sauty A; Pasche A; Egger B; Aedo Lopez V; Letovanec I; Beigelman-Aubry C; Nicod LP; Lazor R
Respiration; 2020; 99(2):181-186. PubMed ID: 31914436
[TBL] [Abstract][Full Text] [Related]
15. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.
Spain L; Higgins R; Gopalakrishnan K; Turajlic S; Gore M; Larkin J
Ann Oncol; 2016 Jun; 27(6):1135-1137. PubMed ID: 26951628
[TBL] [Abstract][Full Text] [Related]
16. Use of Checkpoint Inhibitors in a Kidney Transplant Recipient with Metastatic Cancer.
Ong SC; Mannon RB
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1190-1192. PubMed ID: 32205320
[No Abstract] [Full Text] [Related]
17. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
[TBL] [Abstract][Full Text] [Related]
18. Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.
Loupret T; Boisseau R; Lopez JG; Bertin P; Vergne-Salle P
In Vivo; 2024; 38(3):1451-1453. PubMed ID: 38688588
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
20. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.
Venkatachalam K; Malone AF; Heady B; Santos RD; Alhamad T
Transplantation; 2020 May; 104(5):1041-1047. PubMed ID: 31415036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
